bluebird bio, Inc. (BLUE): Price and Financial Metrics
Today's Latest Price: $60.81 USD
May 28 6:55pm Add BLUE to Watchlist Sign Up POWR Components:
Buy & Hold Grade
Peer Grade Industry Rank BLUE Stock Summary The capital turnover (annual revenue relative to shareholder's equity) for BLUE is 0.05 -- better than only 10.77% of US stocks. BLUE's price/sales ratio is 62.59; that's higher than the P/S ratio of 96.84% of US stocks. BLUE's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 16.09% of US stocks. Stocks with similar financial metrics, market capitalization, and price volatility to bluebird bio Inc are ARVN, RESN, APTX, FPRX, and RGNX. BLUE's SEC filings can be seen here. And to visit bluebird bio Inc's official web site, go to www.bluebirdbio.com. BLUE Price/Volume Stats
3.38B bluebird bio, Inc. (BLUE) Company Bio
Bluebird Bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based immunotherapies. The company was founded in 1992 and is based in Cambridge, Massachusetts.
BLUE Latest News Stream
All News Types Barron's Commentary Corp. News Cramer Downgrade Earnings Insider Buying Mgmt Change New Coverage (Bullish) New Coverage (Neutral) Product News PT Lowered PT Raised PT Set (Bearish) PT Set (Bullish) PT Set (Neutral) Rating Reiterated (Bearish) Rating Reiterated (Bullish) Rating Reiterated (Neutral) Resumes Coverage (Bullish) Resumes Coverage (Neutral) Stock Offering Upgrade
Event/Time News Detail Loading, please wait... Latest BLUE News From Around the Web
Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.
The drug company has not said what it plans to do with the cash, but analysts speculate that it will pursue a gene therapy company worth around $5 billion.
Bluebird (BLUE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Between a string of avoidable problems and instability in the market, bluebird bio might be in for a rough decade.
Bluebird Bio (BLUE) priced an offering of 9.09 million shares of its common stock at $55 each, the company said late on Monday. The post Bluebird Prices New Shares At $55, Seeks To Raise $500 Million appeared first on Smarter Analyst .
Shares of Bluebird Bio Inc. undefined fell 2.9% in premarket trading Monday, after the gene therapy company said it was proposing a public offering of $400…
Read More 'BLUE' Stories Here
BLUE Price Returns
-29.98% Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 1.1498 seconds.